Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer [3]

Journal of the National Cancer Institute

Volumn 95, Issue 16, 2003, Pages 1252-1253

  Muñoz, Alberto ^a   Barceló, Ramón ^a   Rubio, Itziar ^a   Mañe, Joan Manuel ^a   Ferreiro, Josefa ^a   López Vivanco, Guillermo ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYTOTOXIC AGENT; IRINOTECAN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; CANCER ADJUVANT THERAPY; CANCER PATIENT; CASE REPORT; CAUCASIAN; CLINICAL FEATURE; COLORECTAL CANCER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; HAND FOOT SYNDROME; HUMAN; LETTER; MALE; ONYCHOLYSIS; PRIORITY JOURNAL; SKIN MANIFESTATION; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG EFFECT; MIDDLE AGED; NAIL; NAIL DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; HUMANS; MALE; MIDDLE AGED; NAIL DISEASES; NAILS;

EID: 18844470564     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg034     Document Type: Letter

References (5)

1. Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 2000;88: 2367-71.
2. Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 2003;14: 333-7.
3. Chen GY, Chen YH, Hsu MM, Tsao CJ, Chen WC. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol 2001; 145:521-2.
4. Kerr D. Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. Oncology (Huntingt) 2002;16 (12 Suppl 14):12-5.
5. Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Kovats E, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:1307-12.